Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
出版年份 2022 全文链接
标题
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Volume -, Issue -, Pages ijgc-2021-003142
出版商
BMJ
发表日期
2022-01-27
DOI
10.1136/ijgc-2021-003142
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee
- (2021) Jean-Emmanuel Kurtz et al. GYNECOLOGIC ONCOLOGY
- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
- (2020) Charles L. Loprinzi et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives
- (2019) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS)
- (2019) F.T. Roncolato et al. GYNECOLOGIC ONCOLOGY
- Expression III: patients’ expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries
- (2018) G Oskay-Özcelik et al. ANNALS OF ONCOLOGY
- A systematic review of randomised controlled trials evaluating the use of patient-reported outcome measures (PROMs)
- (2018) S. Ishaque et al. QUALITY OF LIFE RESEARCH
- Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer
- (2017) Florence Joly et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
- (2017) Ethan Basch et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lack of Patient-Clinician Concordance in Cancer Patients: Its Relation With Patient Variables
- (2017) Kavita D. Chandwani et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study
- (2017) Felicia T. Roncolato et al. ONCOLOGIST
- A Systematic Review of Health‐Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve
- (2017) Michelle K. Wilson et al. ONCOLOGIST
- Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30
- (2017) Madeleine T. King et al. PHARMACOECONOMICS
- Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
- (2017) Madeleine T. King et al. QUALITY OF LIFE RESEARCH
- Patient-reported outcomes (PRO) in ovarian cancer clinical trials—lost opportunities and lessons learned: Table 1.
- (2016) M. Friedlander et al. ANNALS OF ONCOLOGY
- Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life
- (2016) Kyung-Hye Hwang et al. European Journal of Oncology Nursing
- Symptom management in women with recurrent ovarian cancer: Do patients and clinicians agree on what symptoms are most important?
- (2016) Casey M. Hay et al. GYNECOLOGIC ONCOLOGY
- Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust
- (2016) Johannes M. Giesinger et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
- (2016) Ethan Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30
- (2016) M. T. King et al. QUALITY OF LIFE RESEARCH
- Symptom Burden and Outcomes of Patients With Platinum Resistant/Refractory Recurrent Ovarian Cancer
- (2014) Michael Leonard Friedlander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Development of the Measure of Ovarian Symptoms and Treatment Concerns
- (2014) Madeleine T. King et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
- (2014) Martin R. Stockler et al. JOURNAL OF CLINICAL ONCOLOGY
- What Is the Value of the Routine Use of Patient-Reported Outcome Measures Toward Improvement of Patient Outcomes, Processes of Care, and Health Service Outcomes in Cancer Care? A Systematic Review of Controlled Trials
- (2014) Grigorios Kotronoulas et al. JOURNAL OF CLINICAL ONCOLOGY
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
- (2012) L. C. Hanker et al. ANNALS OF ONCOLOGY
- Automated Symptom Alerts Reduce Postoperative Symptom Severity After Cancer Surgery: A Randomized Controlled Clinical Trial
- (2011) Charles S. Cleeland et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparing higher order models for the EORTC QLQ-C30
- (2011) Chad M. Gundy et al. QUALITY OF LIFE RESEARCH
- A new index of priority symptoms in advanced ovarian cancer
- (2010) Sally E. Jensen et al. GYNECOLOGIC ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started